Saturday 17 October 2026
Export PGNY’s income statement to Excel — free account
Progyny, Inc.
PGNY Healthcare Healthcare Plans
Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
26.86
0.60
−2.18%
Follow PGNY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
32.61 | 37.22 | 20.96 | 29.72 |
P/S ratio |
1.46 | 1.71 | 1.06 | 1.72 | |
P/FCF ratio |
9.57 | 11.47 | 7.45 | 12.63 | |
P/Operating CF |
36.53 | 40.58 | 29.90 | 44.69 | |
P/B ratio |
3.31 | 4.26 | 3.13 | 4.97 | |
Price to Tangible BV |
3.47 | 4.49 | 3.32 | 5.27 | |
EV/Sales |
1.19 | 1.47 | 0.89 | 1.54 | |
EV/EBITDA |
16.14 | 20.99 | 11.33 | 17.15 | |
EV/Operating CF |
7.26 | 9.01 | 5.59 | 10.04 | |
EV/FCF |
7.81 | 9.88 | 6.26 | 11.33 | |
Quick Ratio |
2.84 | 2.62 | 2.07 | 2.06 | |
Current Ratio |
2.96 | 2.73 | 2.13 | 2.14 | |
Net Debt/EBITDA |
(15.44) | (18.22) | (6.11) | (5.69) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.74 | 1.91 | 1.81 | 1.78 | |
Operating CF/Net income |
3.65 | 4.34 | 1.90 | 1.80 | |
Capex/Depreciation |
(5.60) | (3.12) | (4.28) | (3.83) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.37% | 19.37% | 14.52% | 14.06% | |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
10.27% | 10.93% | 6.00% | 5.84% | |
Graham Net Nets |
0.21 | 0.15 | 0.18 | 0.11 | |
Graham Number |
9.83 | 9.67 | 9.95 | 11.25 | |
Earnings Yield |
3.07% | 2.69% | 4.77% | 3.36% | |
Free Cash Flow Yield |
10.45% | 8.72% | 13.42% | 7.92% | |
Revenue per Share |
3.64 | 3.72 | 4.06 | 4.48 | |
Operating CF per Share |
0.59 | 0.63 | 0.57 | 0.65 | |
Capex per Share |
(0.05) | (0.07) | (0.08) | (0.08) | |
Free Cash Flow per Share |
0.53 | 0.57 | 0.49 | 0.57 | |
Cash per Share |
4.01 | 3.62 | 2.78 | 3.03 | |
Shareholders Equity per Share |
6.51 | 6.02 | 5.43 | 5.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.51 | 6.02 | 5.43 | 5.80 | |
Free Cash Flow |
45.99 | 48.59 | 39.60 | 44.21 | |
Working Capital |
411.52 | 349.38 | 265.81 | 272.93 | |
Capital Expenditures |
(4.68) | (5.61) | (6.35) | (6.22) | |
Net Current Asset Value |
386.79 | 325.38 | 242.56 | 250.44 | |
EV/EBIT |
17.60 | 22.21 | 11.96 | 18.03 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
21.56 | 25.79 | 14.24 | 20.10 | |
| Other line items | |||||
Average Receivables |
266.61 | 227.81 | 281.68 | 264.66 | |
Average Payables |
126.78 | 109.58 | 151.77 | 146.28 | |
Average Assets |
727.60 | 674.77 | 714.31 | 738.39 | |
Average Common Equity |
497.44 | 469.05 | 453.25 | 484.14 |
Columns are period end dates